he European Union (EU) on Friday defended its ban on 700 generic drugs made by GVK Biosciences on grounds of data inaccuracy in clinical trials, but hoped that a way out could be found for restarting a deferred effort to revive free trade negotiations with India...The ban on the drugs was based on scientific and not trade considerations and in accordance with the advice of the scientific committee of the European Medicines Agency (EMA), Cesare Onestini, acting head of delegation of the EU to India, said in a statement.